Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L9LS for malaria prevention in young infants in western Kenya
PACTR202410517100221Phase 2Not yet recruiting
- Sponsor
- Office of Clinical Research Policy and Regulatory Operations
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in malaria comparing L9LS with Placebo (2 arms). Primary endpoints: Safety after L9LS administration and Clinical malaria over 14 weeks. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
L9LS
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR202410517100221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202410517100221.